CompletedPhase 2NCT00072579
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Istvan Molnar, MDWake Forest University Health Sciences
- Intervention
- sargramostim(biological)
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2003 – 2007
Study locations (15)
- CCOP - Western Regional, Arizona, Phoenix, Arizona, United States
- CCOP - Bay Area Tumor Institute, Oakland, California, United States
- CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
- Regional Radiation Oncology Center at Rome, Rome, Georgia, United States
- CCOP - Central Illinois, Decatur, Illinois, United States
- Kentuckiana Cancer Institute, PLLC, Louisville, Kentucky, United States
- MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States
- Alamance Cancer Center, Burlington, North Carolina, United States
- Hugh Chatham Memorial Hospital, Elkin, North Carolina, United States
- Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
- Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States
- Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
- CCOP - Columbus, Columbus, Ohio, United States
- Cancer Centers of the Carolinas - Eastside, Greenville, South Carolina, United States
- CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00072579 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics